Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

THE PRPC / PDK1 / TACE SIGNALING AXIS AT THE CROSS-ROAD OF SEVERAL AGGREGATE-PRONE PROTEIN-ASSOCIATED NEURODEGENERATIVE DISEASES

PrPC&PDK1

Neurodegenerative diseases such as Alzheimer's, Prion, Parkinson's diseases, Amyotrophic Lateral Sclerosis, Spino- cerebellar Ataxia and Fronto-temporal Dementia make up a group of pathologies with distinct etiologies and pathophysiological features characterized by the accumulation in the nervous system of abnormal proteins that are toxic for...

Funding Programme
JPND
Start Date
End Date
Total Funding
€ 1 461 047
European Countries Involved

The role of eEF1A in synapse function, maintenance, and synucleinopathy

EaSYFUN

Synucleinopathies are neurodegenerative conditions characterized by an accumulation of the protein alpha-synuclein, including Parkinson's disease and dementia with Lewy bodies. A long asymptomatic phase precedes the onset of invalidating symptoms. Early diagnostics and treatments are hampered by an incomplete understanding of the pathophysiological...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 235 853
European Countries Involved

Towards an Integrative Model of the Relationship Between Episodic Memory and Novelty Detection Through a Behavioural and Neuropsychological Approach

DENOVO

"As memorizing new information relies on distinguishing the new from the familiar, novelty detection is closely tied to memory. Yet, the exact nature of this link remains unclearare they two sides of the same function or rather distinct yet interacting processes? Critically, there are different types of novelty: absolute (new stimulus) or...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 175 920
European Countries Involved

Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS

TREM2MEDS

TREM2MEDS emerges from the ERC PoC 2022 project TREM2ENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimers Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 2 499 721
European Countries Involved

Training Network on Automatic Processing of PAthological Speech

TAPAS

There are an increasing number of people across Europe with debilitating speech pathologies (e.g., due to stroke, Parkinson's, etc). These groups face communication problems that can lead to social exclusion. They are now being further marginalised by a new wave of speech technology that is increasingly woven into everyday life but which is not...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 3 856 029
European Countries Involved

Translational Research Network in Motor Disorder Rehabilitation: Advancing understanding of variability in motor control and learning, to enhance clinical practice

TReND

The theoretical understanding of human motor control and learning has a strong impact on the diagnosis and treatment of motor disorders, and vice versa. Recent progress has been made in the understanding of motor control and learning, particularly with respect to understanding the functional role of neuro-behavioural variability that is inherent to...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 2 462 968

Two-Photon Excited Near-Infrared Emissive Multifunctional Gold Nanoclusters for Imaging and Photothermal Treatment for Alzheimer's Disease

PERSONA

Neurodegenerative diseases are a global epidemic with significant health, social and economic implications and despite intensive research, there is still no cure for them. Alzheimers disease (AD) is the most prevalent neurological disorder having symptoms of the progressive memory loss, neuronal cell death, loss of immune response and cognitive...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 211 754
European Countries Involved

UNDERSTANDING THE CAUSES OF THE RNA GAIN OF FUNCTION DISEASES

RNA DISEASES

It is now increasingly clear that most of our genome is transcribed, but that only a small portion is associated with protein coding gene. Indeed, recent analysis indicate that long non-coding RNA outnumbered by five fold the coding RNA sequences. Despite this abundance, very little is known on the function of these long non-coding RNA. The aim of...

Funding Programme
EU-FP7
Start Date
End Date
Total Funding
€ 1 499 920
European Countries Involved

Unlocking cognition by Pulsatile GnRH in Alzheimer's DiseasE

UPGRADE

Cognitive decline associated with Alzheimer disease (AD) and other age-related dementias affects ~55 million people worldwide, and is a growing problem in aging European societies. However, most drugs fail at clinical trial, and approved treatments aimed at controlling or reversing pathological changes in the brain do not improve cognition in...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Unravelling ApoE4 contribution to tau-mediated synaptic degeneration in AD by combining advanced proteomics and super resolution microscopy

SynApoE

Alzheimers disease (AD) is one of the biggest scientific and socio-economic challenges of the 21st century. Currently, there is no cure. Aggregates of amyloid- and tau protein, along with neuroinflammation/gliosis, are hallmarks of AD that lead to synaptic and neuronal loss as the basis for cognitive decline. The latter correlates closely with the...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 498 449
European Countries Involved

Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

ADDIA

The French SME Amoneta Diagnostics has previously developed a diagnostic kit for Alzheimer’s disease (AD) based on two blood biomarkers that are scientifically proven to be associated with AD. The company holds the intellectual property for specific fluorescent probes that can detect these biomarkers in small amounts of blood using flow cytometry....

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 4 998 625
European Countries Involved

VIrTual BrAin PErfusion: Assessing cerebrovascular function by High Performance Computing from 3D brain vessel network data for vascular-targeted drug development in neurodegenerative diseases.

VITAE

With the recent discovery that brain blood flow decreases — in a statistical and epidemiologic sense — before accumulation of neurotoxic deposits (e.g. amyloid and tau) and before any measurable cognitive deficits, the brain vascular system is increasingly recognized as a key player in the development of Alzheimer’s Disease (AD). This opens the way...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 149 738
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).